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respectively. Each of the three factors and the BG item discrim-
inated between those patients who preferred inhaled insulin and
those who preferred injectable insulin (all p < 0.001). Factors
one and three and the BG item demonstrated the ability to detect
change from baseline (injectable treatment) to following treat-
ment with inhaled insulin (all p < 0.001). Factor analysis and
interscale correlations indicated that the 16 items could be
summed to a total IDSQ score. Cronbach’s alpha for the total
score was 0.93. CONCLUSION: The IDSQ is a reliable and
valid instrument to assess insulin delivery system satisfaction in
patients with type-1 diabetes.
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OBJECTIVES: Public health education is a cornerstone in
primary prevention of diabetes mellitus (DM). However, valid
and reliable tools to evaluate outcomes of DM education among
the general public are lacking. We aim to evaluate the reliability
and validity of the General Diabetes Knowledge Test (GDKT)
for use among subjects with and without DM. METHODS: The
GDKT is a 36-item questionnaire (range 0–100) constructed
based on existing public DM education materials and covers six
content areas: overview, risk factors, symptoms, complications,
management and monitoring (for both Type-1 and 2 DM). To
achieve wide representation, English-speaking subjects (aged >
21) were recruited by convenience sampling at a public health
promotion event. The GDKT was ﬁrst administered to 54 DM
and 42 non-DM subjects. Eighteen subjects voluntarily partici-
pated in retest (all were DM). Internal consistency of GDKT was
assessed using Kuder-Richardson Formula 20 (KRF20). Item dif-
ﬁculty was assessed by calculating the ratio of number of correct
answers to number of respondents, range 0.00 (most difﬁcult) to
1.00 (least difﬁcult) and compared between DM and non-DM
subjects using Students’ t-test. Test-retest reliability was assessed
using intraclass correlation coefﬁcient (ICC). Construct validity
was assessed using a known-group approach where DM subjects
were expected to have higher GDKT scores than non-DM sub-
jects. RESULTS: Internal consistency of GDKT was high (KRF20
= 0.9289). Item difﬁculty ranged from 0.59–0.97 and was sig-
niﬁcantly different (p < 0.05) between subjects with and without
DM for 8 items. Test-retest reliability was moderate (ICC = 0.54,
median = 94.4, range = 72.2–100.0, 95% CI: 0.77). Mean scores
at ﬁrst (91.8 ± 9.83) and second (93.3 ± 1.24) administrations
were not signiﬁcantly different (p = 0.38). As expected, DM sub-
jects reported better mean (±SD) GDKT scores (90.8 ± 11.35)
compared to non-DM subjects (85.7 ± 20.80) although the dif-
ference was not statistically signiﬁcant (p = 0.13). CONCLU-
SION: The internal consistency and construct validity of the
GDKT was demonstrated in this study.
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OBJECTIVES: The aim of this study was evaluate the long-term
costs and clinical outcomes of using either insulin aspart or
human insulin (HI) at mealtimes in patients with type-1 diabetes,
based on the clinical ﬁndings of a multicentre, randomized, open-
label comparative trial in 882 patients, which showed that mean
(±SEM) HbA1c was lower after 12 months with insulin aspart
than with HI (7.78 ± 0.03 versus 7.93 ± 0.05, P = 0.005).
METHODS: Long-term clinical and cost outcomes were esti-
mated using the CORE Diabetes Model, a peer-reviewed, vali-
dated model that employs standard Markov/Monte Carlo
simulation techniques to describe the incidence and progression
of diabetes-related complications. Transition probabilities were
derived from major clinical studies. Published country-speciﬁc
costs, health care resource utilization, clinical data and recom-
mended discount rates were used. A lifetime horizon and third
party payer perspective was taken (direct costs only). Extensive
sensitivity analyses were performed. RESULTS: Discounted
quality-adjusted life expectancy (QALE) was improved by 0.08
to 0.22 years with insulin aspart versus HI in the nine countries
investigated. Lifetime cost savings were observed with insulin
aspart in the Austrian, Dutch, French, and Norwegian settings.
Overall costs were increased with insulin aspart versus HI in
Denmark, Finland, Germany, Spain and Sweden, with incre-
mental cost-effectiveness ratios of DKK20,814, €4434, €9553,
€20,916 and SEK32,541 per QALY gained respectively. CON-
CLUSIONS: Improvements in glycemic control associated with
insulin aspart led to improved QALE due to reduced incidence
of complications versus HI. Insulin aspart was projected to be
either cost-saving or cost-effective compared to HI over patient
lifetimes according to accepted international thresholds.
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OBJECTIVES: Using claims data, develop a measure of vari-
ability in insulin use that could be used as a proxy measure of
non-adherence to insulin. Measure the effect of variability of
insulin use on total and diabetes-attributable health care costs in
a managed care population. METHODS: Using a large managed
care administrative claims database, all patients with a prescrip-
tion for long- or intermediate-acting insulin from January, 2000
through June, 2001 were selected (n = 12,336) from among con-
tinuously eligible patients age 18 years and older. Total insulin
units dispensed with each prescription were computed by multi-
plying quantity (ml) from the claims data and strength (units/ml)
from NDC reference data. Units-per-day were computed for each
prescription pair by dividing units dispensed by the number of
days until the next prescription. A time series of units-per-day
was created for each patient during a one year follow-up period.
